Drug-related problems (DRPs) in geriatric patients with type 2 diabetes mellitus (T2DM): a review

Main Article Content

Lathifa Nabila
Sundas Ejaz
Shalahuddin Al Madury


Asthma is an inflammatory airway disease characterized by bronchial hyper-responsiveness, reversible airflow limitation, and respiratory symptoms. Asthma affects 300 million people in developed countries. More than 10% of asthma complaints in children occur at school age. Asthma therapy in children using pharmacological agents is still the main choice until now. However, the response of pediatric patients to asthma treatment varies. In addition to age, organ function, and drug interactions, genetic factors are often associated with drug response variability. This variability can occur due to single nucleotide polymorphisms (SNP) in protein-coding genes that play a role in bioavailability and drug response. Understanding of pharmacogenomics as the basis of individualized medicine aims to avoid adverse drug reactions and maximize drug effectiveness. The existence of genetic variation allows the drug response between individuals to be different. Pharmacogenomics provides important information in individual-based medicine so that it can predict the existence of a population that can respond well to certain drugs and a population that has a higher risk of adverse drug reactions. Implementation of individual treatment can optimize treatment in patients because the dose of treatment and therapeutic options have been adjusted based on individual genetic characteristics.

Article Details

How to Cite
Lathifa Nabila, Sundas Ejaz, & Shalahuddin Al Madury. (2022). Drug-related problems (DRPs) in geriatric patients with type 2 diabetes mellitus (T2DM): a review. Indonesian Journal of Pharmacology and Therapy, 3(2). https://doi.org/10.22146/ijpther.2695


1.van Roozandaal BW, Krass I. Development of an ecidence-based checlist for the detection of drug related problem in tyepe 2 diabetes. Pharm World Sci 2009; 30(5):580-95
2.Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022; 183:109119.
3.Institute for Health Metrics and Evaluation. Indonesia profile. Available from: http://www.healthdata.org/indoneisa
4.Maharani DD, Syafhan NF, Hersunaryati Y. Drug-related problem in hospitalized geriatric with diabetes mellitus. Int J Appl Pharm 2018; 10(1):142-7.
5.Indonesian Ministry of Health. Directorate of Community and Clinical Pharmacy Development, Directorate General of Pharmaceutical and Medical Devices, Indonesian Ministry of Health. Pharmaceutical Care for Diabetes Mellitus. Jakarta: Indonesian Ministry of Health; 2005
6.Pharmaceutical Care Network Europe Foundation: 2006, PCNE classification for drug-related problems version 5.01; 2006.
7.Haugbolle LS, Sorensen EW. Drug-related problems in patients with angina pectoris, type 2 diabetes and asthma: Interviewing patients at home. Pharm World Sci 2006; 28(4):239-47.
8.Indonesian Ministry of Health. Directorate of Community and Clinical Pharmacy Development, Directorate General of Pharmaceutical and Medical Devices, Indonesian Ministry of Health. Guideline on Drugs Therapy Monitoring. Jakarta: Indonesian Ministry of Health; 2009.
9.Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007; 5(4):345-51.
10.Wulandari N, Andrajati R, Supardi S. Faktor risiko umur lansia terhadap kejadian reaksi obat yang tidak dikehendaki pada pasien hipertensi, diabetes, dislipidemia di Tiga Puskesmas di Kota Depok. Jurnal Kefarmasian Indonesia 2016; 6(1):60-7.
11.Isnani N, Muliyani M. Pengaruh karakteristik pasien dengan terjadinya adverse drug reaction (ADR) pada pasien diabetes melitus tipe 2 rawat inap di RSUD Dr. H. Moch. Ansari Saleh, Banjarmasin. JMPI 2018; 4(1):1-6.
12.Monteiro C. Assessment of suspected adverse drug reactions in elderly patients with diabetes mellitus based on a Portuguese spontaneous reporting database: analysis of reporting from 2008 to 2018. Expert Opin Drug Saf 2021; 20(7):845-53.
13.Shareef J, Fernandes J, Samaga L, Khader SA. A Study on adverse drug reactions in hospitalized patients with diabetes mellitus in a multy-speciality teaching hospital. Asian J Pharm Clin Res 2016;9(2):114-7.
14.Ahmed B, Khan MN. Hypoglycemia : its effect on patients with diabetes. ME-JFM 2019; 17(9):18-23.
15.Terauchi Y, Yokote K, Nakamura I, Sugamori H. Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study. Expert Opin Pharmacother 2016; 17(4):463-71.
16.Koper D, Kamenski G, Flamm M, Bohmdorfer B, Sonnichsen A. Frequency of medication errors in primary care patients with polypharmacy. Fam Pract 2013; 30(3):313-9.
17.Rokiban A, Dwiauliaramdini D, Sitijuwariyah S. Analisis Drug Related Problems (DRPs) Pada Pasien Rawat Jalan Diabetes Melitus Tipe 2 di UPT Puskesmas Rawat Inap Gedong Air, Bandar Lampung. JFL 2021; 9(2):134-42.
18.Lira CP, Lolo WA, Wewengkang DS. Potensi rrug - related problems (DRPs) penggunaan obat antidiabetes pada pasien aiabetes mellitus tipe 2 di Instalasi Rawat Inap Rumah Sakit Kalooran GMIM Amurang. Jurnal Ilmiah Farmasi UNSRAT 2017; 6(4):8.
19.McCormack JP, Allan GM, Virani AS. Is bigger better? An argument for very low starting doses. CMAJ 2011; 183(1):65-9.
20.Vrijens B, Urquhart J. Methods for measuring, enhancing, and accounting for medication adherence in clinical trials. Clin Pharmacol Ther 2014; 95(6):617-26.
21.Al-Abri SA, Hayashi S, Thoren KL, Olson KR. Metformin overdose-induced hypoglycemia in the absence of other antidiabetic drugs. Clin Toxicol 2013; 51(5):444-7.
22.Geller AI, Shehab N, Lovegrove MC, Kegler SR, Weidenbach KN, Ryan GJ, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med 2014; 174(5):678-86.
23.Tsai SH, Lin YY, Hsu CW, Cheng CS, Chu DM. Hypoglycemia revisited in the acute care setting. Yonsei Med J 2011; 52(6):898-908.
24.Cipolle RJ, Strand LM, Morley PC. pharmaceutical care practice: the patient-centered approach to medication management. New York: McGraw-Hill, 2015.
25.Cipolle RJ, Strand LM, Morley PC. Pharmaceutical Care Practice The Clinician’s Guide, 2nd ed. New York: McGraw-Hill Education, 2004.
26.Hamilton HJ, Gallagher PF, O’Mahony D. Inappropriate prescribing and adverse drug events in older people. BMC Geriatr 2009; 9:5.
27.Dhyani V, Rohekar MA, Patil SD, Ganachari MS. Inappropriate drug use and its consequences in elderly patients: an overview. IOSR-JPBS 2015; 10(6):44-9.
28.Moral EG, Suárez-Varela MTM, Esteban JAH, Suanes AMP. Inappropriate multiple medication and prescribing of drugs immobile elderly patients living in the community. Aten Primaria 2006; 38(9):476-80.
29.Baldoni ADO, Chequer FMD, Ferras ERA, de Oliviera DP, Pereira LRL, Dorta DJ. Elderly and drugs: risks and necessity of rational use. Braz J Pharm Sci 2010; 46(4):617-32.
30.The American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015; 63(11):2227-46.
https://doi.org/10.1111 / jgs.13702
31.Constans T, Lecomte P. Non pharmacological treatments in elderly diabetics. Diabetes Metab 2007; 33 Suppl 1:S79-86.
32.Geest S De, Sabaté E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs 2003; 2(4): 323.
33.Fitzgerald AA, Powers JD, Ho PM, Maddox PM, Peterson PN, Allen LA, et al. Impact of medication nonadherence on hospitalizations and mortality in heart failure. J Card Fail 2011; 17(8):664-9.
34.Mendes R, Martins S, Fernandes L. Adherence to medication, physical activity and diet in older adults with diabetes: its association with cognition, anxiety and depression. J Clin Med Res 2019; 11(8):583-92.
35.Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353(5):487-97.
36.Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J 2011; 26(3):155-9.
37.Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc 2011; 86(4): 304-14.
38.Shah D, Simms K, Barksdale D, Wu J. Improving medication adherence of patients with chronic heart failure: challenges and solutions. Res Report Clin Cardiol 2015; 6:87-95.
39.Park K, Kim J, Kim B, Kam S, Kim KY, Ha SW, et al. Factors that Affect Medication Adherence in Elderly Patients with Diabetes Mellitus. Korean Diabetes J 2019; 34(1):55-65.
40. Cascorbi I. Drug interactions--principles, examples and clinical consequences. Dtsch Arztebl Int. 2012;109 (33-34):546-56.
41. Cooper DL, Wood RC, Wyatt JE, Harirforoosh S. Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. Eur J Pharm Sci 2014; 53: 28-34.
42. Fritsche A, Schweitzer MA, Hring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. Ann Intern Med 2003; 138(12): 952-9. https://doi.org/10.7326/0003-4819-138-12-200306170-00006
43. Hoel RW, Connolly GRM, Takahashi PY. Polypharmacy management in older patients. Mayo Clin Proc 2021; 96(1):242-56.
44. Nguyen T, Wong E, Ciummo F. Polypharmacy in older adults: practical applications alongside a patient case. J Nurse Pr 2020;16(3):205-9.
45. Geitona M, Latsou D, Toska A, Saridi M. Polypharmacy and adherence among diabetic patients in Greece. Consult Pharm 2018; 33(10):562-71.